NASDAQ:DMRA Damora Therapeutics, Inc. Common Stock (DMRA) Stock Price, News & Analysis $22.94 -0.95 (-3.98%) As of 06/23/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Damora Therapeutics, Inc. Common Stock Stock (NASDAQ:DMRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DMRA alerts:Sign Up Key Stats Today's Range$22.81▼$24.5350-Day Range$20.07▼$27.0052-Week Range$2.45▼$38.33Volume325,734 shsAverage Volume450,933 shsMarket Capitalization$1.41 billionP/E RatioN/ADividend YieldN/APrice Target$42.43Consensus RatingModerate Buy Company Overview Galecto Inc. is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue. Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders. In addition, Galecto is advancing a LOXL2 inhibitor, GB2064, in preclinical studies aimed at addressing unmet needs in hepatic and systemic fibrosis. These molecules leverage targeted delivery and selective inhibition strategies to modulate the fibrotic cascade and the tumor microenvironment. Founded in 2012, Galecto is headquartered in Copenhagen, Denmark, with research and development operations in Cambridge, Massachusetts. The company’s leadership team brings together expertise in molecular biology, medicinal chemistry and clinical development, with board members and executives drawn from both academia and the pharmaceutical industry. Galecto collaborates with academic centers and industry partners to advance its pipeline and explore additional indications for its proprietary inhibitors.AI Generated. May Contain Errors. Read More Damora Therapeutics, Inc. Common Stock Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreDMRA MarketRank™: Damora Therapeutics, Inc. Common Stock scored higher than 37% of companies evaluated by MarketBeat, and ranked 599th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingDamora Therapeutics, Inc. Common Stock has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 2 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialDamora Therapeutics, Inc. Common Stock has a consensus price target of $42.43, representing about 85.0% upside from its current price of $22.94.Amount of Analyst CoverageDamora Therapeutics, Inc. Common Stock has only been the subject of 4 research reports in the past 90 days.Read more about Damora Therapeutics, Inc. Common Stock's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Damora Therapeutics, Inc. Common Stock are expected to decrease in the coming year, from ($1.92) to ($2.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Damora Therapeutics, Inc. Common Stock is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Damora Therapeutics, Inc. Common Stock is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Damora Therapeutics, Inc. Common Stock's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.29% of the float of Damora Therapeutics, Inc. Common Stock has been sold short.Short Interest Ratio / Days to CoverDamora Therapeutics, Inc. Common Stock has a short interest ratio ("days to cover") of 4.14.Change versus previous monthShort interest in Damora Therapeutics, Inc. Common Stock has recently increased by 8.70%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDamora Therapeutics, Inc. Common Stock does not currently pay a dividend.Dividend GrowthDamora Therapeutics, Inc. Common Stock does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A MarketBeat FollowsOnly 1 people have added Damora Therapeutics, Inc. Common Stock to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Damora Therapeutics, Inc. Common Stock insiders have not sold or bought any company stock.Percentage Held by Insiders0.40% of the stock of Damora Therapeutics, Inc. Common Stock is held by insiders.Percentage Held by Institutions14.20% of the stock of Damora Therapeutics, Inc. Common Stock is held by institutions.Read more about Damora Therapeutics, Inc. Common Stock's insider trading history. Receive DMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Damora Therapeutics, Inc. Common Stock and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DMRA Stock News HeadlinesWhat is HC Wainwright's Estimate for DMRA Q2 Earnings?June 15, 2026 | americanbankingnews.comDamora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Receives Outperform Rating from WedbushJune 13, 2026 | americanbankingnews.comElon just crossed $1 trillion. Who's next?Elon Musk is the world's first trillionaire - and Marc Chaikin of Chaikin Analytics believes Frontier AI is what separates the next wave of wealth-builders from those left behind. Zuckerberg, Bezos, Jensen Huang, the Amodeis, and Sam Altman are all owning, building, or leveraging Frontier AI. Marc has put together a free hotlist and hitlist of the stocks he thinks win big and the ones he thinks get cut loose as this technology reshapes the market.June 24 at 1:00 AM | Chaikin Analytics (Ad)Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comDamora Therapeutics: Well-Funded Moonshot For CALR MutationsMay 27, 2026 | seekingalpha.comDamora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsMay 12, 2026 | globenewswire.comDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comDamora Therapeutics Inc.April 24, 2026 | barrons.comSee More Headlines DMRA Stock Analysis - Frequently Asked Questions How have DMRA shares performed this year? Damora Therapeutics, Inc. Common Stock's stock was trading at $23.01 at the beginning of 2026. Since then, DMRA shares have decreased by 0.3% and is now trading at $22.94. How were Damora Therapeutics, Inc. Common Stock's earnings last quarter? Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) issued its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by $0.23. When did Damora Therapeutics, Inc. Common Stock's stock split? Shares of Damora Therapeutics, Inc. Common Stock reverse split on Friday, August 30th 2024.The 1-25 reverse split was announced on Wednesday, August 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Damora Therapeutics, Inc. Common Stock? Shares of DMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Damora Therapeutics, Inc. Common Stock own? Based on aggregate information from My MarketBeat watchlists, some other companies that Damora Therapeutics, Inc. Common Stock investors own include Realty Income (O), Oxford Square Capital (OXSQ), Plug Power (PLUG), AGNC Investment (AGNC), Aberdeen Total Dynamic Dividend Fund (AOD) and Abrdn Global Infrastructure Income Fund (ASGI). Company Calendar Last Earnings5/13/2026Today6/23/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 DMRA's financial health is in the Green zone, according to TradeSmith. DMRA has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DMRA Previous SymbolNASDAQ:GLTO CIK1800315 Webgalecto.com Phone45-7070-5210FaxN/AEmployees40Year Founded2011Price Target and Rating Average Price Target for Damora Therapeutics, Inc. Common Stock$42.43 High Price Target$46.00 Low Price Target$35.00 Potential Upside/Downside+85.0%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($5.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$209.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-428.30% Return on Assets-114.62% Debt Debt-to-Equity RatioN/A Current Ratio22.49 Quick Ratio22.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($110.11) per share Price / Book-0.21Miscellaneous Outstanding Shares61,553,000Free Float61,307,000Market Cap$1.41 billion OptionableNo Data Beta1.46 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:DMRA) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersFour winners over 400%. Here's #5CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highl...Golden Portfolio | SponsoredMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredBig Oil knew about this for 50 yearsIn the 1970s, Chevron, Unocal, and Texaco all drilled the same energy source - and walked away to protect oil ...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredElon Musk, Larry Fink & Brian Armstrong are ALL Piling into ThisElon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...Brownstone Research | SponsoredKarp just filed Form 144On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Damora Therapeutics, Inc. Common Stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Damora Therapeutics, Inc. Common Stock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
